Accelerate Diagnostics, Inc. (AXDX) Stock

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.

Accelerate Diagnostics, Inc. is headquartered in US.

Accelerate Diagnostics, Inc. (AXDX) stock trades at $0.03 with a market capitalization of $859918. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.01, price-to-sales of 0.07. Over the past 52 weeks the stock has ranged between $0.01 and $2.09, and currently trades 98.6% below its 52-week high.

On profitability, Accelerate Diagnostics, Inc. generates a return on equity (ROE) of 131.82% — well above the market average, a sign of a high-quality business, return on capital employed of 1750.00%, an operating margin of -301.85%, a net profit margin of -427.81%.

Official website: acceleratediagnostics.com